Angiodysplasia medical therapy: Difference between revisions
Nikita Singh (talk | contribs) |
Nikita Singh (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{NKS}} | {{CMG}} {{AE}} {{NKS}} | ||
==Overview== | ==Overview== | ||
Treatment is not required for incidentally found, asymptomatic, non-bleeding lesions. However, it is considered for | Treatment is not required for incidentally found, asymptomatic, non-bleeding lesions. However, it is considered for non-bleeding angiodysplasia with symptoms of occult or overt GI bleed. The invasiveness of therapy depends on clinical severity of anemia, hemodynamic stability and recurrence of symptoms. Although endoscopic techniques are the first choice, hormonal therapy, thalidomide and octreotide are the pharmacological options that have been tried for patients with significant co-morbidities who cannot undergo invasive procedures. | ||
==Medical Therapy== | ==Medical Therapy== | ||
Revision as of 15:09, 9 October 2021
|
Angiodysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiodysplasia medical therapy On the Web |
|
American Roentgen Ray Society Images of Angiodysplasia medical therapy |
|
Risk calculators and risk factors for Angiodysplasia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nikita Singh, M.D.[2]
Overview
Treatment is not required for incidentally found, asymptomatic, non-bleeding lesions. However, it is considered for non-bleeding angiodysplasia with symptoms of occult or overt GI bleed. The invasiveness of therapy depends on clinical severity of anemia, hemodynamic stability and recurrence of symptoms. Although endoscopic techniques are the first choice, hormonal therapy, thalidomide and octreotide are the pharmacological options that have been tried for patients with significant co-morbidities who cannot undergo invasive procedures.
Medical Therapy